Sino Biopharmaceutical Limited

As of December 31, 2021, Sino Biopharmaceutical Ltd. carries a market capitalization of 13.74B, placing it among publicly traded companies globally. Its enterprise value stands at 14.33B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sino Biopharmaceutical Ltd.'s next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2021, Sino Biopharmaceutical Ltd. has 941.62M shares outstanding.

These figures are as of December 31, 2021.

As of December 31, 2021, Sino Biopharmaceutical Ltd. maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2021.

Over the twelve months ended December 31, 2021, Sino Biopharmaceutical Ltd. recorded 193.89M in income tax expense.

As of the close on October 22, 2026, Sino Biopharmaceutical Ltd.'s stock has declined approximately 30.86% over the past 52 weeks. The 50-day moving average sits at 14.40, while the 200-day moving average is 13.47.

As of December 31, 2021, Sino Biopharmaceutical Ltd. holds 2.49B in cash and equivalents against 1.91B in total debt, resulting in a net debt position of 183.29M. Total book value stands at 4.77B, with working capital of 1.28B providing operational flexibility.

Sino Biopharmaceutical Ltd.'s most recent stock split took place on September 4, 2020 with a 2:3 split ratio.